Objective: Paracetamol poisoning remains one of the most common and potentially lethal ingestions. N-acetylcysteine (NAC) has been proven to be a highly effective antidote. The aim of this study was to determine the rate of adverse drug reactions (ADR) to intravenous (IV) NAC. Our hypothesis was that IV NAC for the treatment of paracetamol toxicity has a low rate of adverse events. Methods: This was an observational cohort study undertaken by explicit retrospective medical record review. It included patients who presented to the emergency department with paracetamol overdose over the ten-year period from July 1995 to June 2004. The primary outcome measure was the occurrence of an ADR during NAC administration. Adverse drug reactions were classified as minor (including flushing, urticaria, pruritus, bronchospasm, tachycardia, and non-ischaemic chest pain) and major (including hypotension, angio-oedema and death). Data analysis was by descriptive statistics and chi-square analysis using univariate analysis, Fisher's exact test and Mann-Whitney U-test. Inter-rater agreement was checked for 9% of the sample. Results: There were 470 cases of paracetamol poisoning. Of these, 320 received IV NAC. Thirty-six (11%, 95% CI 8-15%) of these patients developed ADRs. There were two major ADRs, one hypotension and one angio-oedema (0.6%, 95% CI 0.02-2%). Two patients died during hospitalisation, but neither had an ADR to NAC. The most common ADRs were urticaria (20), flushing (15), bronchospasm (12), and pruritus (3). None of the variables analysed was a clinically significant predictor of increased ADR risk. Conclusion: Adverse drug reactions after IV NAC infusion occur commonly, but most are minor. Treatment of paracetamol poisoning with IV NAC appears to be safe, however a large prospective study would be required to confirm this. (Hong Kong j.emerg.med.
Introduction
Paracetamol poisoning remains one of the most common lethal ingestions, potentially leading to fulminant hepatic failure and death. Since the mid1970s there has been an increase in the number of paracetamol overdoses, such that paracetamol or paracetamol-containing analgesics have now become the substances most frequently used in deliberate selfpoisoning in the United Kingdom. 1 It has also become increasingly common in other countries including Denmark and Australia. 2, 3 In the United States, the American Association of Poison Control Centers reported more than 127,000 exposures involving paracetamol in 2003 and 214 associated deaths. 4 Paracetamol is metabolised by the hepatic cytochrome P450 enzyme system. It is the toxic metabolite, N-acetyl-p-benzoquinonimine, that leads to hepatotoxicity. This metabolite is usually detoxified by endogenous glutathione but, in overdoses, endogenous glutathione stores are depleted and hepatotoxicity occurs. N-acetylcysteine (NAC) is the recommended treatment for paracetamol poisoning. It has been proven to be a highly effective antidote, especially when administered early following ingestion. [5] [6] [7] Intravenous (IV) NAC is the standard treatment for paracetamol poisoning in Australasia, Asia and in most European countries. 2, [8] [9] [10] [11] Although IV NAC is well tolerated, adverse drug reactions (ADR) have been reported in the literature. [12] [13] [14] [15] [16] [17] These ADR are usually minor anaphylactoid reactions including urticaria, rash, flushing and itchiness. However, more severe reactions including hypotension and angio-oedema have also been reported. Deaths have been reported but appear to have been related to 0.6% 95% 0. 02-2%  20  15  12  3 Keywords: Acetaminophen, acetylcysteine, antidotes accidental administration of an overdose of NAC. 18 The reported rates of ADR with the use of NAC for paracetamol overdose were diverse (4-48%) but sample sizes were generally small. [14] [15] [16] [17] 19 The primary aim of this study was to determine the adverse event rate and type after treatment for paracetamol poisoning with intravenous NAC in an Australian emergency department (ED) population.
Methods
This was an observational cohort study conducted by explicit retrospective medical record review. Patients who presented to the Western Hospital emergency department (a community teaching hospital with annual ED census of ~32,000) with paracetamol overdose in the period from 1 July 1995 to 30 June 2004 were identified by a search of a health information database for a principal inpatient discharge diagnosis of 'paracetamol overdose', 'paracetamol toxicity', or 'paracetamol poisoning'. Records were reviewed to confirm the accuracy of diagnosis and treatment with NAC. Cases with co-ingestions were included, but specific data about the nature of co-ingestions and any relationship with adverse effects were not collected.
Data were collected on an explicit data form by a single researcher (WM) who was not blinded to the study's aims. Data collected included demographics, past history of asthma, atopy or allergy, previous NAC exposure, estimated ingested paracetamol dose in categories (mg/kg), initial paracetamol level (µmol/L) and timing of paracetamol level post-ingestion, the initial rate of NAC infusion, the time of NAC infusion post-ingestion and evidence of hepatic toxicity. As in similar studies, hepatic toxicity was defined as alanine aminotransferase and aspartate aminotransferase greater than twice the normal range at 24 hours postingestion. ADR and their management were also recorded, and 9% of the medical records were reviewed by a second researcher (ZK) to check inter-rater reliability.
The primary outcomes of interest were the rate and type of ADR. Secondary outcomes were the relationships between ADR and the variables collected. ADR were classified as minor (including flushing, urticaria, pruritus, bronchospasm, tachycardia, and non-ischaemic chest pain) and major (including hypotension, angio-oedema and death). Although nausea is commonly experienced, it is difficult to determine whether it is an ADR to NAC or a reaction to the underlying poisoning. We decided to exclude it from our analysis.
During the period being studied, in mid-1999 the rate of administration of the initial 150 mg/kg dose of NAC was changed at the study institution from 15 to 60 minutes, otherwise administration was as per manufacturer's recommendations.
Data analysis was by descriptive statistics and chisquare analysis using univariate analysis, Fisher's exact tests (categorical) and Mann-Whitney U-test using SPSS. This study was approved by the relevant Human Research Ethics Committee.
Results
Sample derivation is shown in Figure 1 . The age of the study population ranged from 15 to 81 years with a median age of 27 years, 73% (233/320) were female. Notably, 39 (12%) had a documented past history of Figure 1 . Sample derivation of the study. Where data were available, the reported ingested doses ranged from 2 g to 50 g with 12% ingesting less than 150 mg/kg, 15% ingesting between 150-199 mg/kg, 27% ingesting between 200-300 mg/kg and 36% ingesting more than 300 mg/kg. The paracetamol level on admission ranged from 1 to 8151 µmol/L. Nineteen patients (6%) showed or developed signs of hepatotoxicity as defined. Two patients died during hospitalisation due to the effects of co-ingested substances, but neither had an ADR to NAC. One patient was transferred for assessment for liver transplantation (0.3%, 95% CI 0.02-2%).
NAC=N-acetylcysteine
The initial NAC infusion was administered over 15 minutes in 42% of cases, over 30 minutes in 6%, over 60 minutes in 50% and over 120 minutes or more in 3% of cases. Thirty-six patients (11%, 95% CI 8-15%) developed an ADR. These are summarised in Table 1 .
The most common ADRs were urticaria (20, 56%), flushing (15, 42%) and bronchospasm (12, 33%). There were two major ADRs: one case of hypotension and one of facial angio-oedema (0.6%, 95% CI 0.02-2%). There were no NAC-related deaths (0%, 95% CI 0-1%). The only variable statistically associated with occurrence of an ADR was age, with patients who were younger being more likely to experience an ADR (median age 25 vs. 28 years, p=0.003) ( Table 2 ). This is unlikely to be clinically relevant.
Twenty patients (56%) who developed an ADR were treated with intramuscular (IM) promethazine, 1 patient (3%) with prochlorperazine and 14 patients (39%) with IV hydrocortisone. Eight patients (22%) received salbutamol via nebuliser and in 1 case IM adrenaline was given (3%). In 27 patients (75%) NAC infusion was paused or the rate of administration lowered. In 5 cases (14%) the NAC infusion was ceased.
Inter-rater reliability of data collection was assessed on 29 records (9% of the sample). Data items analysed were NAC administration, age, gender, rate of NAC infusion, adverse events and disposition. Agreement was 100%, with a kappa for agreement of 1.0.
Discussion
IV NAC has been the standard treatment for paracetamol poisoning in Europe, Asia, Australia and Canada since 1977 but the reported rate of adverse events is highly variable. [14] [15] [16] [17] 19 We found an ADR rate of 12%, with a very low (0.6%) rate of major ADR. There were no NAC-related deaths.
ADR to NAC are well described and commonly occur during the loading dose infusion. 9, 14, 20, 21 They are thought to be anaphylactoid in origin and dose and rate dependent. As found in our study, reported reactions include itching, rash, flushing, and urticaria. More serious side effects including bronchospasm, hypotension and angio-oedema have also been reported and are confirmed by our findings.
The reported adverse event rates with the use of NAC for paracetamol overdose are diverse (4-48%) and vary with study design. The two prospective studies reported ADR rates of 48% 17 and 42% 19 respectively and the retrospective groups reported ADR rates between 3.7-9%. [14] [15] [16] Our study falls between the two. With respect to potentially severe ADR, others have reported rates of 0.005% 12 and 0.01%. 19 We found a slightly higher but still low rate (0.6%). It is likely that the differences in ADR rates reported are due to differences in definition and interpretation of ADR (e.g. inclusion or exclusion of nausea and vomiting as ADR) and omissions in documentation in the retrospective studies: a well-known limitation of this study design. We found no association between the rate of infusion and likelihood of ADR. This is consistent with the finding reported by Kerr et al 19 in their prospective study. The only variable that we found to be associated with ADR was age, with patients who were younger being more likely to have an ADR. This association is unlikely to be clinically relevant. Previous studies 3 identified asthma as a risk factor for developing an ADR to NAC. Our study did not confirm this. This again might be due to variations in self-reported asthma and the limitations of a retrospective study. There was no death due to an ADR related to IV NAC, which was consistent with the published literature.
Our study has some limitations that must be considered when interpreting the results. The main limitations are those of retrospective record reviews, 22 in particular data omissions. We have tried to limit these limitations by careful definition of the study question and sample, explicit data collection forms and assessment of interrater reliability. This study was conducted at a single site, so may not be generalisable to other populations.
Conclusion
Adverse drug reactions after IV NAC infusion occur commonly, but most are minor. Treatment of paracetamol poisoning with IV NAC appears to be relatively safe, however a large prospective study would be required to confirm this.
